Get Regular Updates!
Search
|Killer immunotherapy: fighting cancer with genetic engineering

People

image|

Walter and Eliza Hall Institute of Medical Research

Killer immunotherapy: fighting cancer with genetic engineering

Killer immunotherapy: fighting cancer with genetic engineering

Finding a cure for cancer is no easy feat, but Dr Misty Jenkins has built her career in immunotherapy to do just that.

Killer immunotherapy: fighting cancer with genetic engineering

Since 2016, Misty has led a lab at the Walter and Eliza Hall Institute of Medical Research.

From a young age, Misty was fascinated with how the body works. This fascination inspired her to complete a Bachelor of Science, where she discovered a passion for learning about white blood cells.

Cell snipers

Killer lymphocytes are a subset of white blood cells that protect our bodies from viruses and cancer.

Misty describes them as an army being sent off to destroy invaders in the cell.

Video|Misty Jenkins
Killer white blood cells attack and kill cancer cells

“They’re zooming around in the blood and lymph system, trying to keep us healthy.”

“Most of the time, they do a really good job, but when they don’t, we can develop cancer,” she says.

During her PhD, Misty looked at how the killer lymphocytes arm themselves.

“War is a really good analogy—soldiers play different roles,” she says.

There is a specialised subset called killer T cells that kill cancerous and virus-infected cells.

“I looked at how they choose their weapons.”

Misty says killer T cells destroy their targets by throwing toxic grenades at the cancer cell.

“There are many different kinds of weapons, and during my PhD, I examined what regulates the acquisition of T cell killing machinery.”

View Larger
Image|NIH Image Gallery
A group of killer T cells (green and red) surround a cancer cell (blue, center). The killer T cells attach to cancer cells and spread over them, delivering the “kiss of death” using toxic grenades (red).

“The more we understand how T cells kill, the easier it is for us to manipulate the system.”

Her fascination with these cells led her to cancer immunology-immunotherapy work.

An immunology arms race

“There have been monumental leaps in how we can manipulate our immune system and rearm it against invaders,” Misty says.

“We are now engineering blood cells to arm the immune system against the patient’s own tumour.”

In terms of cancer therapy, treatments for cancer have advanced from surgery to radiation, X-rays and chemotherapy.

“We’ve come such a long way in the last decades in how to manipulate our immune system,” she says.

Misty says immunotherapy will provide a whole new fourth pillar of therapy—harnessing the power of the immune system.

“We are now engineering blood cells to arm the immune system against the patient’s own tumour.”

View Larger
Image|Walter and Eliza Hall Institute of Medical Research
Misty’s lab team at the Walter and Eliza Hall Institute of Medical Research

Misty says scientists and doctors can take a patient’s blood and genetically engineer their white blood cells to redirect them against their own tumour.

“This occurs by giving the white blood cells the receptor they need—the key to fit the lock—of the tumour cells.”

Misty’s projects use a variety of cutting-edge techniques to answer complex scientific problems. She is known widely for her use of live cell microscopy, which is like taking a digital picture of the cells to examine their behaviour.

Her research is aiming to understand how killer lymphocytes acquire the ability to kill and detach from cancer cells.

“We want to learn about the interplay between lymphocytes and other immune cells and the subsequent consequences for the immune system,” she says.

View Larger
Image|Czesia Markieqicz, Walter and Eliza Hall Institute of Medical Research
Misty uses live cell microscopy, which is like taking a digital picture of the cells to examine their behaviour

In recognition of her research excellence, Misty has won numerous awards and funding support, including a prestigious University of Cambridge College Fellowship, and she was one of the 2016 Westpac/AFR Top 100 Women of Influence.

She was most recently awarded the CSIRO Indigenous STEM Professional Career Achievement Award.

Into the future, Misty’s primary focus is her lab and discovering innovations to bring new cancer immunotherapy to clinical trials.

The biggest success for this type of therapy, Misty says, has been for blood cancers, and there has only been moderate success in solid cancers, as they have additional challenges.

“My lab is examining how we might apply this therapy to the brain,” she says.

Vital science VIDEO

Republish

Creative Commons Logo

Republishing our content

We want our stories to be shared and seen by as many people as possible.

Therefore, unless it says otherwise, copyright on the stories on Particle belongs to Scitech and they are published under a Creative Commons Attribution-NoDerivatives 4.0 International License.

This allows you to republish our articles online or in print for free. You just need to credit us and link to us, and you can’t edit our material or sell it separately.

Using the ‘republish’ button on our website is the easiest way to meet our guidelines.

Guidelines

You cannot edit the article.

When republishing, you have to credit our authors, ideally in the byline. You have to credit Particle with a link back to the original publication on Particle.

If you’re republishing online, you must use our pageview counter, link to us and include links from our story. Our page view counter is a small pixel-ping (invisible to the eye) that allows us to know when our content is republished. It’s a condition of our guidelines that you include our counter. If you use the ‘republish’ then you’ll capture our page counter.

If you’re republishing in print, please email us to let us so we know about it (we get very proud to see our work republished) and you must include the Particle logo next to the credits. Download logo here.

If you wish to republish all our stories, please contact us directly to discuss this opportunity.

Images

Most of the images used on Particle are copyright of the photographer who made them.

It is your responsibility to confirm that you’re licensed to republish images in our articles.

Video

All Particle videos can be accessed through YouTube under the Standard YouTube Licence.

The Standard YouTube licence

  1. This licence is ‘All Rights Reserved’, granting provisions for YouTube to display the content, and YouTube’s visitors to stream the content. This means that the content may be streamed from YouTube but specifically forbids downloading, adaptation, and redistribution, except where otherwise licensed. When uploading your content to YouTube it will automatically use the Standard YouTube licence. You can check this by clicking on Advanced Settings and looking at the dropdown box ‘License and rights ownership’.
  2. When a user is uploading a video he has license options that he can choose from. The first option is “standard YouTube License” which means that you grant the broadcasting rights to YouTube. This essentially means that your video can only be accessed from YouTube for watching purpose and cannot be reproduced or distributed in any other form without your consent.

Contact

For more information about using our content, email us: particle@scitech.org.au

Copy this HTML into your CMS
Press Ctrl+C to copy

We've got chemistry. Want something physical?